OR4A5 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Capsaicin | 404-86-4 | sc-3577 sc-3577C sc-3577D sc-3577A | 50 mg 250 mg 500 mg 1 g | $94.00 $173.00 $255.00 $423.00 | 26 | |
Capsaicin is known to activate TRPV1 (transient receptor potential cation channel subfamily V member 1), leading to calcium influx. OR4A5, as an olfactory receptor, can be sensitive to intracellular calcium levels. High calcium can lead to desensitization of G protein-coupled receptors (GPCRs), thereby inhibiting OR4A5 signaling. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine is an endosomal acidification inhibitor, which can increase the pH of endosomes. This disruption of endosomal acidification can impact GPCR recycling, including OR4A5, leading to reduced receptor availability at the cell surface and decreased function. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin directly activates adenylyl cyclase, which increases cAMP levels. Elevated cAMP can lead to the activation of PKA, which can phosphorylate GPCRs like OR4A5, leading to receptor desensitization and inhibition of its functional activity. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
As a non-selective beta-adrenergic antagonist, propranolol can decrease cAMP levels by inhibiting adenylyl cyclase via GPCR signaling, which can reduce OR4A5 activity if OR4A5 signaling is cAMP-dependent. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $442.00 | 3 | |
Pertussis toxin irreversibly ADP-ribosylates the alpha subunit of the Gi/o class of G proteins, inhibiting their activity. As OR4A5 is a GPCR, its signaling could be inhibited due to the disruption of Gi/o protein-mediated inhibition of adenylyl cyclase, thereby reducing signaling efficacy. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
Suramin inhibits G protein activation by binding to GPCRs, including OR4A5, and preventing G protein coupling, leading to a decrease in OR4A5-mediated signal transduction. | ||||||
SCH 23390 | 125941-87-9 | sc-200408 sc-200408A | 5 mg 25 mg | $175.00 $719.00 | 2 | |
SCH-23390 is a dopamine D1 receptor antagonist that also inhibits GPCR signaling, including OR4A5, by blocking G protein-coupling and subsequent intracellular signaling cascades. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $62.00 $260.00 | 21 | |
Ketoconazole inhibits cytochrome P450 enzymes, which are involved in steroid biosynthesis. This inhibition can lead to altered membrane lipid composition and potentially affect GPCR function, including OR4A5. | ||||||
Phloretin | 60-82-2 | sc-3548 sc-3548A | 200 mg 1 g | $63.00 $250.00 | 13 | |
Phloretin inhibits various transporters and may alter the cell membrane's biophysical properties. This can indirectly influence GPCR activity, such as OR4A5, by changing the receptor's microenvironment and its ability to signal. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Amiloride is a diuretic that blocks epithelial sodium channels. By altering ionic gradients, amiloride can modify the membrane potential and indirectly affect GPCR signaling, potentially reducing OR4A5 activity. | ||||||